Bob Nelsen, Anne Wojcicki join $20M round for longevity startup hoping to slow down aging of the ovary
Having helped birth some of the earliest anti-aging upstarts, Bob Nelsen has found another new idea to love in the burgeoning space.
The ARCH managing director is among a syndicate pouring $20 million of Series A cash into Gameto, a New York-based biotech whose stated mission is to reprogram ovarian cells to slow down the aging of the ovary — which is very much “accelerated” compared to other organs, according to the company.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.